What Champions Oncology, Inc. does.

We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.

At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.

Revenue and profit, by fiscal year.

More on CSBR.

• Champions Oncology, Inc. summary
• Champions Oncology, Inc. financial statements
• Champions Oncology, Inc. key metrics
• Champions Oncology, Inc. health scores and style box
• Champions Oncology, Inc. earnings
• Champions Oncology, Inc. dividends
• Champions Oncology, Inc. valuation
• Champions Oncology, Inc. ownership and insiders
• Champions Oncology, Inc. peers

Figures from Champions Oncology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.